FDA approves new hepatitis C medication

Zepatier, a new hep C treatment is $54,000. For a 12-week treatment course. The Associated Press reports that the approval is “good news for patients because the growing competition should crimp the sky-high prices for hepatitis C drugs!” Bill Chesnut, MD

 FDA approves new hepatitis C medication

The Wall Street Journal (1/28, Loftus, Subscription Publication) reports that the Food and Drug Administration has approved Merck & Co.’s Zepatier (elbasvir and grazoprevir), a once-daily, single-tablet combination therapy for hepatitis C. The drug is approved for patients with the most common type of hepatitis C in the US, genotype 1, as well as genotype 4. Zepatier has a list price of $54,000 for a 12-week course of treatment.

The AP (1/29, Johnson) reports that the approval is “good news for patients, because the growing competition should crimp the sky-high prices for hepatitis C drugs, and the additional option means there’s one that will work for nearly every subgroup of people with hepatitis C.”

AMA Wire newsletter January, 2016.